Use of ipilimumab in the treatment of melanoma

Utkarsh H. Acharya, Joanne M Jeter

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalClinical Pharmacology: Advances and Applications
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 9 2013

Fingerprint

United States Food and Drug Administration
Melanoma
CTLA-4 Antigen
Investigational Therapies
Monoclonal Antibodies
Clinical Trials
Therapeutics
Pharmaceutical Preparations
ipilimumab

Keywords

  • Immunotherapy
  • Ipilimumab
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Use of ipilimumab in the treatment of melanoma. / Acharya, Utkarsh H.; Jeter, Joanne M.

In: Clinical Pharmacology: Advances and Applications, Vol. 5, No. SUPPL. 1, 09.08.2013, p. 21-27.

Research output: Contribution to journalArticle

@article{c3dfe437ec0e41f7a0bed114ab3bb014,
title = "Use of ipilimumab in the treatment of melanoma",
abstract = "Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.",
keywords = "Immunotherapy, Ipilimumab, Melanoma",
author = "Acharya, {Utkarsh H.} and Jeter, {Joanne M}",
year = "2013",
month = "8",
day = "9",
doi = "10.2147/CPAA.S45884",
language = "English (US)",
volume = "5",
pages = "21--27",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Use of ipilimumab in the treatment of melanoma

AU - Acharya, Utkarsh H.

AU - Jeter, Joanne M

PY - 2013/8/9

Y1 - 2013/8/9

N2 - Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.

AB - Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.

KW - Immunotherapy

KW - Ipilimumab

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84884870085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884870085&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S45884

DO - 10.2147/CPAA.S45884

M3 - Article

AN - SCOPUS:84884870085

VL - 5

SP - 21

EP - 27

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

IS - SUPPL. 1

ER -